HK1212389A1 - Carbonic anhydrase ix-related markers and use thereof ix - Google Patents

Carbonic anhydrase ix-related markers and use thereof ix

Info

Publication number
HK1212389A1
HK1212389A1 HK15102061.3A HK15102061A HK1212389A1 HK 1212389 A1 HK1212389 A1 HK 1212389A1 HK 15102061 A HK15102061 A HK 15102061A HK 1212389 A1 HK1212389 A1 HK 1212389A1
Authority
HK
Hong Kong
Prior art keywords
carbonic anhydrase
related markers
markers
anhydrase
carbonic
Prior art date
Application number
HK15102061.3A
Other languages
English (en)
Chinese (zh)
Inventor
Paul C Mcdonald
Frances E Lock
Shoukat Dedhar
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of HK1212389A1 publication Critical patent/HK1212389A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
HK15102061.3A 2011-10-24 2015-03-02 Carbonic anhydrase ix-related markers and use thereof ix HK1212389A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550807P 2011-10-24 2011-10-24
PCT/US2012/061711 WO2013063130A1 (fr) 2011-10-24 2012-10-24 Marqueurs associés à l'anhydrase carbonique ix et leur utilisation

Publications (1)

Publication Number Publication Date
HK1212389A1 true HK1212389A1 (en) 2016-06-10

Family

ID=47356277

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102061.3A HK1212389A1 (en) 2011-10-24 2015-03-02 Carbonic anhydrase ix-related markers and use thereof ix

Country Status (7)

Country Link
US (1) US10195174B2 (fr)
EP (1) EP2771488B1 (fr)
JP (1) JP6259764B2 (fr)
CN (1) CN104136629B (fr)
CA (1) CA2853283C (fr)
HK (1) HK1212389A1 (fr)
WO (1) WO2013063130A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
JP6277894B2 (ja) * 2014-07-08 2018-02-14 株式会社島津製作所 上皮間葉転換の有無を判別する方法
CN104630380B (zh) * 2015-03-06 2016-08-24 河北医科大学第四医院 碳酸酐酶iv在制备肺腺癌诊断制剂中的应用
CN107158388B (zh) * 2017-07-11 2021-03-23 上海市第一人民医院 MIIP pS303阻断剂在制备抗肿瘤药物中的应用
AU2020348365A1 (en) * 2019-09-18 2022-04-07 Biomarker Strategies, Llc. Methods to improve patient response to immune checkpoint inhibitors and functional tests to predict response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO2003019192A1 (fr) 2001-08-27 2003-03-06 The Trustees Of Boston University Appareil, composition et procede de profilage proteomique
EP1461082A4 (fr) 2001-12-03 2006-06-28 Abgenix Inc Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
DK2594265T3 (en) 2002-11-26 2015-12-21 Inst Virology CA IX-specific inhibitors
WO2006056766A2 (fr) 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnostic du cancer de la prostate
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2094719A4 (fr) 2006-12-19 2010-01-06 Genego Inc Nouveaux procédés pour une analyse fonctionnelle de données expérimentales à haut débit et groupes de gènes identifiés à partir de ceux-ci
WO2008127716A2 (fr) 2007-04-13 2008-10-23 George Mason Intellectual Properties, Inc. Stat3 comme indicateur théranostique
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US20090123439A1 (en) * 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
JP2010178650A (ja) * 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
US20100317533A1 (en) * 2009-06-05 2010-12-16 British Columbia Cancer Agency Branch Biomarkers of cancer metastasis
NZ705645A (en) * 2010-01-11 2016-05-27 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2841217C (fr) 2010-07-09 2018-09-25 Metasignal Therapeutics Inc. Nouveaux composes de sulfonamide destines a l'inhibition de la croissance tumorale metastatique

Also Published As

Publication number Publication date
JP6259764B2 (ja) 2018-01-10
EP2771488A1 (fr) 2014-09-03
WO2013063130A1 (fr) 2013-05-02
JP2014532864A (ja) 2014-12-08
CA2853283A1 (fr) 2013-05-02
US20140303103A1 (en) 2014-10-09
US10195174B2 (en) 2019-02-05
CN104136629B (zh) 2021-08-24
EP2771488B1 (fr) 2018-03-28
CA2853283C (fr) 2022-04-26
CN104136629A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
ZA201308930B (en) Nitrogen containing compounds and their use
HK1187337A1 (zh) 喹唑啉二酮及其應用
PT2730564T (pt) Aminas heterocíclicas e suas utilizações
EP2707102A4 (fr) Agents de ciblage de l'anhydrase carbonique et leurs procédés d'utilisation
IL225713A0 (en) Cytopheric cartridge and its use
HK1198827A1 (en) Dyrk1 inhibitors and uses thereof dyrk1
IL229844B (en) Anti-psgl-1 antibodies and their use
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
GB201111705D0 (en) Compounds and their use
EP2749633A4 (fr) Composition ayant une stabilité de mousse améliorée et son utilisation
GB201110783D0 (en) Methods and uses
EP2738255A4 (fr) Peptide issu de erap1 et son utilisation
IL232362A0 (en) The chemical composition containing fluorine and its use
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
ZA201400223B (en) Improved spreader and use thereof
GB201116774D0 (en) Uses and methods
HK1212389A1 (en) Carbonic anhydrase ix-related markers and use thereof ix
EP2841571A4 (fr) Anhydrase carbonique ii humaine présentant une stabilité physique accrue
EP2697386A4 (fr) Conception et utilisation de pepducine
GB201114448D0 (en) Compounds and their use
EP2693879A4 (fr) Migrastatines et leurs utilisations
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
GB201108490D0 (en) Methods and uses